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Abstract
Background: Liver transplantation is the definitive treatment for many end-stage liver diseases. However, the life-
long immunosuppression needed to prevent graft rejection causes clinically significant side effects. Cellular
immunomodulatory therapies may allow the dose of immunosuppressive drugs to be reduced. In the current
protocol, we propose to complement immunosuppressive pharmacotherapy with third-party multipotent adult
progenitor cells (MAPCs), a culture-selected population of adult adherent stem cells derived from bone marrow
that has been shown to display potent immunomodulatory and regenerative properties. In animal models, MAPCs
reduce the need for pharmacological immunosuppression after experimental solid organ transplantation and
regenerate damaged organs.
Methods: Patients enrolled in this phase I, single-arm, single-center safety and feasibility study (n = 3-24) will
receive 2 doses of third-party MAPCs after liver transplantation, on days 1 and 3, in addition to a calcineurin-
inhibitor-free “bottom-up” immunosuppressive regimen with basiliximab, mycophenolic acid, and steroids. The
study objective is to evaluate the safety and clinical feasibility of MAPC administration in this patient cohort. The
primary endpoint of the study is safety, assessed by standardized dose-limiting toxicity events. One secondary
endpoint is the time until first biopsy-proven acute rejection, in order to collect first evidence of efficacy. Dose
escalation (150, 300, 450, and 600 million MAPCs) will be done according to a 3 + 3 classical escalation design
(4 groups of 3-6 patients each).
Discussion: If MAPCs are safe for patients undergoing liver transplantation in this study, a phase II/III trial will be
conducted to assess their clinical efficacy.
Background
Liver Transplantation
Liver transplantation remains the only definitive treat-
ment for a number of diseases, including end-stage
chronic liver disease, acute liver failure, or limited hepatic
neoplasms, with patient and graft survival rates exceeding
75% after five years [1,2]. However, liver transplantation
is burdened by the need for life-long immunosuppression
in order to prevent graft rejection. All drugs currently
used for immunosuppression cause significant clinical
side effects. Besides their well-known intrinsic toxicities
(e.g., neurotoxicity of tacrolimus and renal toxicity of
ciclosporin [3-5]), they also increase the risk for cancer
and opportunistic infections [6-11]. The long-term over-
all success of liver transplantation is frequently deter-
mined by complications related to immunosuppressive
drug therapy. Yet, immunosuppressants are indispensable
to maintain graft function and to cover aberrations in
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transplanted organ.
Growing numbers of patients in need of a liver graft are
faced with a continuous shortage of donor organs. In the
Eurotransplant area, for instance, only 1631 transplant
livers were available for 2641 patients on the waiting list
in 2009 [12]. To overcome this shortage, criteria for the
acceptance of donors have been liberalized, e.g., in terms
of prolonged ischemia time, increased donor age, or the
presence of clinically significant donor liver steatosis.
While increasing the donor pool, these “marginal” organs
are also associated with higher incidences of primary
graft dysfunction and major complications [13-15]. Here,
we propose a novel protocol involving treatment of liver
transplant recipients with multipotent adult progenitor
cells (MAPCs) with the goal of reducing the dose of
immunosuppressive drugs and of supporting liver regen-
eration in marginal grafts.
Multipotent adult progenitor cells
MAPCs belong to the family of mesenchymal stem cells
(MSCs) and are cultured from bone marrow aspirates
[16-18]. The clinical-grade MAPC product (MultiStem
®,
A t h e r s y sI n c . ,C l e v e l a n d ,O h i o ,U S A )t ob eu s e di nt h i s
study is isolated from a single bone marrow aspirate and
cultured with heat inactivated fetal bovine serum (FBS)
and growth factors EGF and PDGF. Cells display a lin-
ear expansion rate to 65 population doublings or greater
before senescence. Doubling times average 20 hours
during expansion. Cells are used after 30 population
doublings and tested by flow cytometry, in vitro immu-
nomodulatory assays and cytogenetics. Moreover, exten-
sive safety testing in immunodeficient animal models is
performed [19-21].
MAPCs share immunosuppressive functions with
MSCs [16], they have been shown to suppress T-cell
proliferation in vitro and ameliorate graft-versus-host
disease (GvHD) in small animal models [22]. First clini-
cal trials with MAPCs have already been initiated to
treat GvHD and Crohn’s disease [21]. Moreover,
MAPCs have regenerative properties, contributing to
vascular regeneration in models of limb ischemia [23],
improving cardiac function after myocardial infarction
[24], and contributing to the regeneration of injured
livers through their ability to differentiate into hepato-
cyte-like cells [25].
MSCs and MAPCs have been successfully applied in
preclinical heart transplantation models in combination
with various immunosuppressants [26-29]. Our group
has demonstrated that MSCs and MAPCs induce long-
term graft acceptance when applied together with myco-
phenolic acid [26,27]. In contrast, calcineurin inhibitors
(CNIs) have been shown to abrogate the immunosup-
pressive effect of MSC therapy in this and other animal
models [30]. The current study protocol therefore calls
for a CNI-free, “bottom-up” immunosuppressive regi-
men combined with the MAPC infusions.
“Bottom-up” immunosuppression
Current standard clinical protocols for post-transplant
immunosuppression vary between institutions, conti-
nents and indications. However, most induction therapies
include corticosteroids that are subsequently tapered
over the first months. CNIs, such as ciclosporin A or
tacrolimus, are the mainstay of immunosuppression,
sometimes in combination with mycophenolic acid
(MPA). Further treatment options are also available, like
e.g. thymoglobulin. In addition, anti-CD25 monoclonal
antibodies can be used to block activated T cells in the
first week after the operation [31]. Because standard
immunosuppressive treatment is often reliant on CNI-
based regimens, which can cause among other things
renal impairment, hypertension, and hyperglycemia
[32-35], efforts have been made to reduce CNI exposure
for liver transplant recipients [36]. Indeed, a proportion
of patients can achieve graft acceptance without CNIs,
while acute rejection episodes in the remaining patients
can be treated with high-dose steroids and intensification
of the baseline immunosuppressive regimen, without
graft loss.
“Bottom-up” immunosuppression, then, refers to a
CNI-free induction protocol consisting of steroids, myco-
phenolic acid and basiliximab. CNIs are introduced only
when needed, e.g. in case of biopsy-proven acute rejec-
tion. This approach is feasible in liver transplantation,
because of its lower immunogenicity in comparison to
other types of organ transplants and because of the low
risk of graft loss or permanent graft damage by acute
rejection episodes. The “bottom-up” regimen has already
been applied successfully in clinical studies [37,38] and is
particularly valuable for high-MELD (Model for End-
stage Liver Disease) patients with increased risk of infec-
tions or renal dysfunction. In view of the synergistic
interplay of MSCs with mycophenolic acid, and because
CNIs have been shown to abolish the beneficial effect of
MSCs in animal models, this study will use “bottom-up”
immunosuppression in combination with MAPCs. We
hypothesize that MAPC infusions will help to signifi-
cantly delay the introduction of CNIs or allow to avoid
them altogether.
Methods & Design
Objectives and Endpoints
The primary objective of this study is to assess the
safety of MAPC infusions in patients undergoing liver
transplantation. The secondary objective is to provide
preliminary evidence regarding the study product’se f f i -
c a c yb ya n a l y z i n gt h et i m et of i r s tb i o p s y - p r o v e na c u t e
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Page 2 of 10rejection up to day 90. Furthermore the incidence of
malignancies or any other unexpected side effects until
day 365 will be investigated. After closing this study, all
participants will be enrolled in a follow-up protocol that
assesses long-term safety of MAPCs over an additional 6
years. This two-step follow-up approach has been
designed in close collaboration with the responsible reg-
ulatory authorities. Immunomonitoring will be per-
formed on blood samples from all participating patients
to assess the anti-donor immune response, the composi-
tion of circulating T cell subpopulations, the anti-donor
antibody response and to identify a putative biomarker
signature that is associated with transplant tolerance.
Study Design
This is a phase I, single-arm, single-center safety and
feasibility study based on a classical 3 + 3 dose escala-
tion design. Safety of MAPC infusions is assessed by the
occurrence of a dose-limiting toxicity (DLT) event
(Figure 1) within 30 days after administration of the first
MAPC dose. Because the focus in this study is on safety,
ac o n s e r v a t i v ed o s ee s c a l a t i o ns c h e m er a t h e rt h a na n
accelerated titration design was chosen. The starting
d o s eo f2×1 5 0m i l l i o nM A P C s( M u l t i S t e m
®)p e r
patient has already been administered to patients for
various indications, with no side effects observed so far.
This dose corresponds to doses that have been shown
to prolong graft survival in animal models. The maxi-
mum dose of 2 × 600 million MAPCs is still at least
50% lower than the maximum-tolerated dose in
laboratory animals and similar to MSC doses already
injected into patients [39].
Each patient will receive 2 doses of MAPCs. The first
dose will be administered during liver transplantation
directly into the portal vein after graft reperfusion. As
the study begins with liver transplantation this day is
defined as day 1 (in contrast to most preclinical investi-
gation that defines the day of the transplant as “day 0”).
The second dose will be administered intravenously on
day 3 in the intensive care unit. Three patients will be
treated with the starting dose of 2 × 150 million third-
p a r t yM A P C s .I fn oD L Ti so b s e r v e di na n yo ft h e3
patients of this cohort, the second cohort of 3 patients
will be treated with 2 × 300 million MAPCs, continuing
with the third cohort with 2 × 450 million MAPCs and
the fourth cohort with a final dose of 2 × 600 million
MAPCs. The dose escalation design is illustrated in
Figure 2.
Should one patient experience a DLT after 3 patients
have been enrolled in any cohort, another 3 patients will
be enrolled in the same dose group after consultation
with the data safety monitoring board. If no further toxi-
city occurs, the next 3 patients will be enrolled at the
next dose level. If a total of 2 or more patients experience
a DLT, either after 3 or 6 patients have been enrolled, the
s t u d yw i l lb ec l o s e da n dt h ed o s eo ft h ep r e v i o u sc o h o r t
will be considered the maximum-tolerated dose.
If no toxicities occur at all, the maximum dose admi-
nistered in the study, i.e., 2 × 600 million MAPCs per
patient, will be considered the maximum-tolerated dose
Pulmonary toxicity  
PaO2/FiO2 ratio < 200 (days 1, 2, 3, and 4) 
FEV1 (days 10 and 30) 
Re-intubation after 48 h post extubation 
Lung embolism assessed according to the European guidelines [50] 
Portal infusional toxicity 
Protal vein flow Vmax [cm/s] = 0 
Resistive Index RI >= 1 
Retrograde arterial flow  
Arterial occlusion 
Venous occlusion 
RI < 0.5 and Systolic Acceleration Time (SAT) > 0.08 s 
Systemic toxicity 
Anaphylactic shock 
Figure 1 Dose-limiting toxicity (DLT) events.Clinical events of toxicity related to MAPC infusions. If more than one DLT event occurs in a dose
cohort, the study will be stopped.
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Page 3 of 10and the study will be closed. Using the dose escalation
scheme described above, between 3 and 24 patients will
be enrolled in this study, with 12 patients being the
optimal scenario. The study protocol was designed
according to the declaration of Helsinki and approved
by the local ethics committee.
Trial Population
Patients of both genders and any ethnic origin aged 18
years or older will be screened at the Department of
Surgery, University Hospital Regensburg, and enrolled
into the study if they meet the eligibility criteria given in
Figure 3. All suitable patients will be informed about the
study during a regular outpatient visit and asked for
their willingness to participate. Specific study related
risks such as the possible transmission of xenopathogens
following cell culture with bovine serum will be
explained. At our institution annually 70-80 patients are
placed on the European Liver Transplant Waiting List.
Therefore, to enroll 3-24 patients for the study, a
recruitment period of 12 months is anticipated.
Interventions
Pre- and Intraoperative Data
Patients enrolled in this study will not need to undergo
additional screening visits or clinical investigations in
addition to standard pre-transplant work-up. Standard-
of-care examinations for patients on the Liver Trans-
plant Waiting List will be performed, including baseline
clinical data (demographics, medical history, current
medication), physical examination, laboratory examina-
tions, infection screening, urinalysis, electrocardiogram,
echocardiography, chest X-ray, triple-phase abdominal
computed tomography with intravenous and oral con-
trast, pulmonary function tests, and arterial blood gas
analysis. Intraoperative data (warm and cold ischemia
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Figure 2 Dose escalation design. Three patients will be treated with the starting dose. If no DLT occurs, the next cohort will be treated with
the next MAPC dose level. If one DLT occurs in a cohort, a second cohort of 3 patients will be treated with the same MAPC dose level. The
study will be stopped if more than one DLT event is recorded after enrolling at most 6 patients.
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Page 4 of 10time, blood loss, requirement for blood products, inci-
sion-to-suture time) and donor data (age, serum sodium
and gamma-GT levels, body mass index, infection status,
cause of death, time on intensive care unit) will also be
documented.
Treatment Regimen
Immunosuppression will be tailored to the individual
needs of each patient in a “bottom-up” approach. The
immunosuppressive protocol used in this study is already
being applied at our center in patients with an expected
low risk for rejection (MELD score > 25, particularly with
preoperative renal dysfunction). Prior to liver reperfusion,
500 mg prednisolone will be administered intravenously.
The cell product stored in liquid nitrogen at our hospital
blood bank will be thawed by a qualified person and pre-
pared for application. After liver reperfusion, the trans-
plant surgeon will infuse the first MAPC dose from the
freshly thawed cryobag directly into the portal vein using
a small catheter.
On days 1 and 5, 20 mg of basiliximab will be adminis-
tered for induction therapy as one key element of the
institution’s immunosuppressive regimen. There is a
growing body of evidence indicating that basiliximab can
impair the development of transplant tolerance by pre-
venting the development of regulatory T cells [40-43].
Since we anticipate that omitting basiliximab will not
Inclusion criteria 
Patients >18 years of age undergoing allogeneic liver transplantation from a cadaveric donor 
Absence of any familial, sociological or geographical condition potentially hampering 
compliance with the study protocol and follow-up schedule 
Written informed consent prior to any study procedures 
Exclusion criteria 
Known allergies to bovine or porcine products 
Patients older than 65 years of age 
Patients listed in a high-urgency status that would not allow proper preparation of the study 
interventions 
Patients receiving a secondary liver graft (retransplantation) 
Double organ transplant recipients 
Pre-existing renal failure that requires or has required hemodialysis within the last year 
Pulmonary function: FEV1, FVC, DLCO ≤50% predicted 
Cardiac function: left ventricular ejection fraction ≤50% 
HIV seropositive, HTLV seropositive, varicella virus active infection, or syphilis active 
infection.  
History of any malignancy (including lymphoproliferative disease and hepatocellular 
carcinoma) except for squamous or basal cell carcinoma of the skin that has been treated 
with no evidence of recurrence  
Unstable myocardium (evolving myocardial infarction), cardiogenic shock  
Females capable of childbearing (hormonal status and gynecological consultation required) 
Males not agreeing to use contraception for the duration of the study  
Patient is pregnant, has a positive serum β-hCG, or is lactating 
Known current substance abuse (drug or alcohol) 
Prisoner 
Use of an investigational agent within 30 days prior enrolment 
Concurrent enrolment in any other clinical trial 
Any psychiatric, addictive or other disorder that compromises ability to give informed consent 
Figure 3 Inclusion and exclusion criteria of the study.
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Page 5 of 10influence MAPC toxicity, we have chosen to retain basi-
liximab yet to focus solely on safety in this study. More
preclinical data is then needed to establish a causal rela-
tionship between basiliximab and putative MAPC effects.
If it turns out that MAPCs depend on intact interleukin-
2 signaling, the application of basiliximab in a subsequent
efficacy study has to be critically discussed.
Maintenance immunosuppression will be conducted
with 2 g/d mycophenolic acid (MPA) given as a split
dose twice daily. Steroids at a dose of 1 mg/kg body
weight will be commenced on day 1 and tapered succes-
sively. On day 3, the second MAPC dose will be admi-
nistered intravenously in the intensive care unit. All
patients will be monitored in a fully equipped tertiary
intensive care unit before and for at least 48 hours after
the cell infusion (see Figure 4).
Follow-up
Thirteen follow-up visits will be performed during the
first 30 days after transplantation. Blood samples will be
collected, clinical examinations performed, and adverse
events recorded as detailed in Table 1. Dose-limiting
toxicity (DLT) assessments will be performed on days 1,
2, 3, 4, 10, and 30. Per protocol, biopsies will be per-
formed during liver transplantation and on days 4 and
10, with additional biopsies obtained whenever clinically
necessary. Four additional outpatient visits are planned
to further evaluate the study patients (including screen-
ing for malignancies) until day 365 (Table 1). Additional
blood samples will be obtained to investigate surrogate
markers of the patient’s immune response status. This
translational immunomonitoring will be performed on
days 1, 3, 10, and 30, including mixed lymphocyte reac-
tions to evaluate anti-donor reactivity, flow cytometry to
describe the recipients’ leucocyte repertoire, serum
analysis to screen for anti-donor antibodies and cyto-
kines. Moreover, we will analyze peripheral blood sam-
ples for genes that have recently been associated with
tolerance in liver and kidney transplantation such as
CKLRF1, CLIC3 and TOAG-1 [44-48]. Using specific
donor characteristic (e.g. differences in gender or MHC
haplotypes) circulating MAPC will be tracked in blood
samples by rtPCR. Further labeling of transfused MAPC
is not planned at this stage for safety reasons. We
expect MAPC to be cleared quickly from the recipient
because they have been susceptible to NK-cell lysis and
were detected only transiently in most animal experi-
ments [49].
Dose-Limiting Toxicity
To assess the safety of MAPC infusions, we have defined
putative toxicity events anticipated to be specific for stem
cell-based therapy in liver transplantation. This dose-lim-
iting toxicity (DLT), which covers specific events that
model significant toxicity likely caused by MAPC infu-
sions, is designed as a ‘high-barrier score’ that aims to
detect toxicities of the highest clinical significance that
will halt the further development of this therapy option.
The most important consideration is that MAPCs
might pool in the first capillary bed after injection and
cause micro- or macroembolism. To monitor for poten-
tial embolus formation, we have specified diagnostic pro-
cedures to examine the liver and lung after intraportal
and intravenous injection, respectively. Toxicity related
to intraportal infusion will be assessed by Doppler ultra-
sound determining the maximum portal blood flow, the
resistive index (RI) of the hepatic artery, and the presence
of any vascular occlusion or changes in the flow patterns.
We will monitor lung toxicity by assessing the necessity
of reintubation and the occurrence of pulmonary emboli
according to published European guidelines after intrave-
nous cell infusion [50]; moreover, the PaO2/FiO2 ratio
[51] will be tightly monitored to detect lung damage.
Because MAPCs are derived from a third-party donor
and were cultured with bovine serum and recombinant
growth factors, MAPC infusion may cause anaphylactic
reactions or shock, and systemic toxicity will therefore
also be assessed (Figure 1). Three more patients will be
enrolled into a dose cohort if one DLT event occurs. The
study will be stopped if more than one DLT event occurs
after enrolling 6 patients or if the data safety monitoring
committee recommends to do so. The feasibility and
validity of the DLT events have been validated in 200 ret-
rospectively analyzed patients having received liver grafts
without experimental cellular therapy (unpublished data).
Data safety monitoring committee
An independent data safety monitoring committee will
be installed to monitor the study progress. The
days 1 2 3 4 5 
Liver  Transplantation  X      
Basiliximab  X      X 
Prednisolone X X X X X 
Mycophenolic  acid X X X X X 
MAPC  X  X    
Figure 4 Immunosuppressive treatment regimen. Basiliximab
will be applied on days 1 and 5 after transplantation; 2 g
mycophenolic acid (MPA) will be applied per day given as a split
dose. Steroids will be started on postoperative day 1 and tapered
by month 6 after liver transplantation, MAPC infusions will be
administered into the portal vein during transplantation and later
intravenously on day 3.
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Page 6 of 10committee will include basic scientists and clinicians not
otherwise involved in the trail. Members of this group
will review the clinical and investigational data to ensure
that participants are not exposed to undue risk. The
data safety monitoring committee will review the data
up to day 30 for each dosing cohort and will then give
written recommendation on whether or not to continue
the study. Members of the committee will also recom-
mend on whether the next dosing cohort should start
enrolment or whether the current cohort should be
expanded. The data safety monitoring committee can
recommend stoppage of the study for reasons of patient
safety at any time. Whenever adverse events occur, the
principal investigator and the study team will communi-
cate those to the data safety monitoring committee in
due time. If an adverse event is serious (SAE) or unex-
pected (SUSAR), the responsible authorities will be
informed. About 10 SAEs might be expected in each
liver transplant recipient transplanted with high MELD
score during the first 30 days.
Risk-Benefit Assessment
Although pharmacological immunosuppression has con-
tinuously evolved over the last three decades, it is still
associated with a significant intrinsic risk. Side effects
include opportunistic (mainly biliary) infections in the
short-term and drug-specific side effects or malignancies
in the intermediate and long-term [9,52]. Thus, even in
this era of established immunosuppressive pharma-
cotherapy, there is still significant room for improvement
of current immunosuppressive protocols. Moreover,
long-term survival of liver transplant recipients has not
improved over the past decade, suggesting novel strate-
gies are needed to extend life after transplantation.
Adherent, non-hematopoietic bone marrow stem cells,
including MAPCs and MSCs, have been shown to bene-
ficially modulate the anti-donor immune response in
organ transplantation and to promote tissue regenera-
tion in vitro and in vivo [26-29,53]. The first promising
experiences using MAPCs in patients with autoimmune
disorders, such as inflammatory bowel disease or GvHD,
have been reported. Other conditions, especially those
requiring regenerative support, such as critical limb
ischemia or myocardial infarction, have also successfully
been treated with MAPCs in animal models [23,24]. It is
therefore clinically promising to test the application of
MAPCs in a phase I study after allogeneic liver trans-
plantation. The risk of applying MAPCs to this patient
population is unknown. However, so far no significant
side effects of MAPC infusions have been observed in
either animal disease models or in phase I and II clinical
studies in humans. Thus, we believe that the potential
benefit of administering MAPCs to patients after allo-
geneic liver transplantation is significant and that the
associated risks of the cell infusions are low and toler-
able. In summary, the benefits of MAPC infusions pro-
mise to outweigh the risks.
Discussion
Standard pharmacological immunosuppression can
achieve good survival of patients and liver grafts [1,2,12].
This success of interdisciplinary transplant medicine has
made liver transplantation a standard-of-care clinical
therapy for end-stage liver disease. Long-term side effects
of organ transplantation with chronic immunosuppres-
sive therapy, however, are clinically significant and limit
the overall success of the procedure [3-11]. Therefore,
the objective of this study is to implement cellular immu-
nomodulation therapy as an adjunct to standard pharma-
cological immunosuppression. The ultimate goal of this
approach is to significantly reduce drug-based immuno-
suppression and achieve a state of long-term transplant
acceptance completely without immunosuppression for
some recipients. To apply MAPCs in the clinic, we think
that the calcineurin inhibitor-free “bottom-up” immuno-
suppression regime is essential because animal data sug-
gest a synergistic effect of MSCs with mycophenolic acid
and an antagonistic effect of MSCs with cyclosporine
[26,27,30,54]. Therefore, in our view the liver is the most
promising organ to establish a MAPC-based therapy
Table 1 Assessment schedule
Study Phase LTx EOT Post-Treatment Phase Follow-Up
Visit no. 1 2 3 4 5-9 10 11 12 13 14 15 16 17
Study days 1 2 3 4 5-9 10 14 20 30
±1 0d
90
±3 0d
180
±3 0d
270
±3 0d
365
±3 0d
MAPC treatment X X
DLT assessment X X X X X X
Laboratory X X X X X X X X X X X X X
Doppler ultrasound X X X X X X X X
Liver biopsy X X X
Immunomonitoring X X X X X
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Page 7 of 10because it is the only organ that can be transplanted
without using calcineurin inhibitors routinely. In case
acute rejection occurs despite MAPC treatment, this can
be treated with a low risk of graft loss or permanent graft
damage justifying the attempt to reduce drug-based
immunosuppression with MAPCs.
The main focus of this phase I study is on safety and
feasibility of infusing a population of MAPCs with sus-
pected immunomodulative and regenerative features.
Therefore, the primary endpoint is the occurrence of
dose-limiting toxicity events. To explore for immunolo-
gical efficacy, secondary endpoints include the time until
first biopsy-proven acute rejection (up to day 90). From
another view, one of the secondary endpoints is to look
for evidence of malignant transformation of the infused
cells that would severely limit their further use. Long-
term persistence of MAPC might be associated with a
higher potential of malignant transformation and recipi-
ent-anti-donor-sensitization. Therefore we will attempt
to track circulating MAPCs in peripheral blood samples
by rtPCR. Further labeling of the transfused cells cannot
be justified in this phase I trial for reasons of patient
safety.
The hypothesis is that MAPCs can prevent acute
rejection episodes in the early post-transplant phase by
interaction with recipient lymphocytes. We anticipate
shifting the immune response towards a state of perma-
nent graft acceptance that makes the escalation of phar-
macological immunosuppression unnecessary. Moreover,
we expect MAPCs to ameliorate ischemia/reperfusion
damage to the graft, thereby avoiding late complications,
such as hepatorenal syndrome and bile duct ischemia.
The regenerative abilities of MAPCs could also reduce
the occurrences of primary graft dysfunction and accel-
erate normalization of liver synthesis function especially
in marginal liver grafts.
In summary, the expected clinical efficacy of MAPC
infusions as an adjunct to established immunosuppres-
sive pharmacotherapy is substantial and the potential
benefits outweigh the expected risks. MAPCs have
already been administered in about 50 patients with no
specific severe side effects reported [55]. MSCs, which
can be considered similar to MAPCs in terms of their
safety profile, have been administered in over 200
patients with no reported malignancies or severe side
effects [56]. If the lack of dose-limiting toxicities can be
confirmed in the present study, we intend to conduct a
second, larger study to assess the immunomodulatory
and regenerative efficacy of MAPC infusion in liver
transplantation. A positive outcome from MAPC ther-
apy trials in terms of reducing the need for pharmacolo-
gical immunosuppression would represent a major
advancement for liver transplant recipients.
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